Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
9.03
-0.28 (-2.96%)
At close: Jun 27, 2025, 4:00 PM
9.13
+0.11 (1.16%)
After-hours: Jun 27, 2025, 7:12 PM EDT
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $20.04M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $43.72M. In the year 2024, Syndax Pharmaceuticals had annual revenue of $23.68M.
Revenue (ttm)
$43.72M
Revenue Growth
n/a
P/S Ratio
19.03
Revenue / Employee
$161,933
Employees
270
Market Cap
776.58M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SNDX News
- 3 days ago - Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - GlobeNewsWire
- 15 days ago - Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 - GlobeNewsWire
- 16 days ago - Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 - GlobeNewsWire
- 22 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Syndax Announces Participation in June Investor Conferences - GlobeNewsWire
- 6 weeks ago - Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) - GlobeNewsWire
- 6 weeks ago - Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Syndax Announces Participation in May Investor Conferences - GlobeNewsWire